Stephens Downgrades Centessa Pharmaceuticals (CNTA) to Equal Weight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts CNTA Hot Sheet
Price: $40.50 --0%
Rating Summary:
8 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 23 | New: 12
Rating Summary:
8 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 23 | New: 12
Join SI Premium – FREE
Stephens analyst Sudan Loganathan downgraded Centessa Pharmaceuticals (NASDAQ: CNTA) from Overweight to Equal Weight.
For an analyst ratings summary and ratings history on Centessa Pharmaceuticals click here. For more ratings news on Centessa Pharmaceuticals click here.
Shares of Centessa Pharmaceuticals closed at $27.58 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- KeyBanc Downgrades Vistra Energy (VST) to Sector Weight
- Crude Inventory Fell 0.9 Million Barrels Last Week - EIA
- DigitalOcean (DOCN) PT Lowered to $100 at UBS
Create E-mail Alert Related Categories
DowngradesRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
